Jin Rong Jie·2025-08-07 18:41Core Viewpoint - Fosun Pharma's stock price is currently at 26.37 yuan, reflecting a decline of 0.98% from the previous trading day, with a trading volume of 724 million yuan [1] Company Overview - Fosun Pharma is a large pharmaceutical enterprise focused on drug manufacturing and research, covering the entire pharmaceutical health industry chain [1] - The company's main products include anti-tumor drugs, cardiovascular system drugs, and central nervous system drugs [1] Recent Developments - Fosun Pharma's subsidiary, Fosun Hani, has recently received FDA approval to conduct Phase I clinical trials for HLX43, an injectable drug for the treatment of thymic cancer [1] - HLX43 is a PD-L1 targeted antibody-drug conjugate intended for the treatment of advanced/metastatic solid tumors [1] - The company plans to conduct global multi-center clinical research for this indication in Australia, Japan, and the United States [1] - As of June 2025, the cumulative R&D investment for this new drug is expected to be approximately 182 million yuan [1]